Q-omics provides the consensus-scored SPATA18 profile across patient tissues and cancer cell-line models. SPATA18 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPATA18 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SPATA18 RNA expression shows 18,524 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where SPATA18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA18 survival associations across molecular data types. SPATA18 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA18 RNA expression–survival associations across cancer types. High SPATA18 expression shows unfavorable associations in LGG, but favorable associations in KIRC, KIRP, UCEC, KICH and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPATA18 RNA expression.
This table summarizes SPATA18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SPATA18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA18 shows lower tumor expression in HNSC, LUSC, LUAD and BRCA and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher SPATA18 RNA expression in tumor versus normal tissue (log2 FC = +1.972, t-test p < 0.001).
This table shows molecular features associated with SPATA18 in patient tissues and cancer cell lines. In patient samples, SPATA18 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
